Last month, we introduced the Commercial Growth Framework and the hidden assumption embedded in most launch forecasts: that resistance will decline over time.
It usually doesn’t.
Most teams are waiting for an inflection point as if it will arrive on schedule: after enough awareness, enough selling, enough quarters in market.
But the inflection point is not a timing event.
It’s a belief event. And most teams don’t realize they’ve missed it until the numbers tell them.
Time, activity, and awareness alone don’t reduce resistance.
In healthcare, inertia is the default. Growth accelerates only when the market stops defending the status quo.
In this briefing:
- Market belief matters
- Time is not a strategy
- Your blindspot will cost you
- Sonder Capital Founding Partner explains why most launches stall
- Case Study: Exubera
- Signs your market is ready (next time)
Understanding and Using the Inflection Point
Most teams treat the inflection point like a timing event: a quarter when momentum kicks in, a revenue threshold where adoption starts to scale, or a natural payoff for a strong launch.
But the inflection point is not a time milestone.
It’s a market belief milestone.
It occurs when the market crosses the Market Belief Threshold; the moment when staying the same feels harder to defend than changing.
What Changes After the Threshold Is Crossed
Once the threshold is crossed, the market starts behaving differently. Decision-makers no longer require full re-education. Switching feels safer than staying. The current standard feels increasingly inadequate—dangerous, even.
Expansion becomes easier because the “why change” argument is pervasive inside the clinical space.
Revenue stops being episodic and starts becoming sustained.
The Blind Spot That Can Cost You
Inside the company, conviction forms early. Outside the company, belief often lags.
The organization sees the data, knows the product, and understands the opportunity. The market sees switching risk, operational disruption, internal politics, and a still-defensible status quo.
That gap is where bad forecasts are born.
Assumptions feel evidence-based inside the building while still being aspirational outside it.
And by the time the gap becomes visible in the numbers, correction is far more expensive.
Exubera: When the Market Doesn’t Believe It Has a Problem
Pfizer invested eleven years and billions of dollars developing Exubera, the first FDA-approved inhaled insulin. The pharmacology worked. Regulators cleared it. The promise: eliminate injections for millions managing diabetes.
The market wasn’t interested.
Physicians balked at pulmonary testing. Patients avoided the bulky inhaler. Payers questioned the cost.
But more importantly: No one had ever convinced the market that injections were a problem worth solving.
The existing standard still felt acceptable. So nothing changed.
By late 2007, less than two years post-launch, Pfizer withdrew Exubera. Sales: $12 million. Write-off: $2.8 billion.
Growth doesn’t accelerate because something is better. It accelerates when the current way becomes unacceptable.
What Determines Whether the Threshold Is Crossed?
The real question is not whether time will reduce resistance. It’s what conditions would have to change in the market for resistance to decline at all?
In the next Launch Code, we will answer that directly through the five conditions that reduce forecast risk—and show how the Commercial Growth Scorecard helps leadership teams assess whether those conditions are actually forming.
Do you need commercial launch insurance?
Find out with a Pivotal Commercial Design Review (PCDR).
